Infinity Pharmaceuticals Financial Ratios

Infinity Pharmaceuticals Inc -- USA Stock  

USD 1.81  0.03  1.63%

We strongly advise you to harness analysis of Infinity Pharmaceuticals fundamentals to see if markets are presently mispricing the organization. We found thirty-five available reported financial drivers for Infinity Pharmaceuticals which can be compared to its competitors. To make sure the equity is not overpriced, please check out all Infinity Pharmaceuticals fundamentals including its Shares Owned by Institutions, Net Income, Short Ratio, as well as the relationship between Price to Sales and Debt to Equity . Please also validate Infinity Pharmaceuticals Price to Earning to confirm the company can sustain itself down the road.Use Infinity Pharmaceuticals to protect against small markets fluctuations. The stock experiences somewhat bearish sentiment, but market may correct it shortly. Check odds of Infinity Pharmaceuticals to be traded at $1.7557 in 30 days

Infinity Pharmaceuticals Valuation Over Time

Enterprise Value

Infinity Pharmaceuticals Company Summary

Infinity Pharmaceuticals competes with NantKwest, Del Mar, Denali Therapeutics, VBI Vaccines, and Vascular Biogenic. Infinity Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for patients with difficult-to-treat diseases in the United States. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts. Infinity Pharmaceuticals operates under Biotechnology classification in USA and traded on NASDAQ exchange. It employs 56 people.

Infinity Pharmaceuticals Z Score vs Number of Shares Shorted

Infinity Pharmaceuticals Inc is currently regarded as number one stock in z score category among related companies. It is currently regarded as number one stock in number of shares shorted category among related companies making about  319,355  of Number of Shares Shorted per Z Score.

Infinity Pharmaceuticals Systematic Risk

The output start index for this execution was twelve with a total number of output elements of five. The Beta measures systematic risk based on how returns on Infinity Pharmaceuticals correlated with the market. If Beta is less then 0 Infinity Pharmaceuticals generally moves in the opposite direction as compared to the market. If Infinity Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Infinity Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Infinity Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Infinity Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark. View also all equity analysis or get more info about beta statistic functions indicator.
< 16% 

Chance of Financial Distress

Infinity Pharmaceuticals Inc has less than 16 (%) percent chance of experiencing financial distress in the next 2 years of operations. More Info


Infinity Pharmaceuticals Growth Changes

EPS Diluted Growth

EPS Growth

NCFO Growth


Compare Infinity Pharmaceuticals To Peers
Adelene Perkins Chairman of The Board, CEO and Pres, MBA
Joseph Pearlberg Vice President - Clinical Development, Ph.D
More Executives

Opportunity Range

February 23, 2018 Opportunity Range